Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: A pathway-based analysis

Molecular Carcinogenesis

Volumn 51, Issue 7, 2012, Pages 546-552

  Dong, Jing ^a   Hu, Zhibin ^a   Shu, Yongqian ^a,b   Pan, Shiyang ^b   Chen, Wenping ^c   Wang, Yi ^c   Hu, Lingmin ^a   Jiang, Yue ^a   Dai, Juncheng ^a   Ma, Hongxia ^a   Jin, Guangfu ^a   Shen, Hongbing ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Nanjing Thoracic Hospital   (China)

Author keywords

DNA repair; NSCLC; Polymorphism; Survival

Indexed keywords

ATM PROTEIN; METHYL CPG BINDING PROTEIN; MRE11 PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DNA REPAIR; EXCISION REPAIR; GENE LOCUS; HUMAN; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 84861846758     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20819     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Wei Q, Frazier ML, Levin B. DNA repair: A double-edged sword. J Natl Cancer Inst 2000; 92: 440-441.
3. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
4. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 1091-1099.
5. Zhang M, Hu Z, Huang J, et al. A 3′-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010; 16: 1236-1244.
6. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-2601.
7. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 118-123.
8. Sreeja L, Syamala VS, Syamala V, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol 2008; 134: 645-652.
9. Giachino DF, Ghio P, Regazzoni S, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007; 13: 2876-2881.
10. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-316.
11. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
12. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281-288.
13. Hu Z, Wang H, Shao M, et al. Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: A haplotype-based analysis. Hum Mutat 2007; 28: 431-440.
14. Dong J, Dai J, Shu Y, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 31: 1080-1086.
15. Seker H, Butkiewicz D, Bowman ED, et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001; 61: 7430-7434.
16. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354-1357.
17. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843-1850.
18. Leng S, Stidley CA, Willink R, et al. Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation. Cancer Res 2008; 68: 3049-3056.
19. van de Vaart PJ, Belderbos J, de Jong D, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-166.
20. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst 2000; 92: 1764-1772.
21. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 23-43.
22. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754.
23. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009; 27: 5808-5815.
24. Chang PM, Tzeng CH, Chen PM, et al. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009; 100: 278-283.
25. Qiu L, Wang Z, Shi X. Associations between XPC polymorphisms and risk of cancers: A meta-analysis. Eur J Cancer 2008; 44: 2241-2253.
26. Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 2008; 7: 141-148.
27. Shen J, Desai M, Agrawal M, et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1614-1619.
28. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.